Pharsight

1. Epidiolex patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP15784111A	2021-04-29	James Poole Limited	Granted and Under Opposition

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10195159	GW RES LTD	Processes and apparatus for extraction of active substances and enriched extracts from natural products	May, 2022 (1 year, 4 months ago)
US11096905	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Oct, 2035 (12 years from now)
US11207292	GW RES LTD	Cannabidiol preparations and its uses	Apr, 2039 (15 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11311498	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US11701330	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US9956184	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US9956185	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US10849860	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US10966939	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US10709673	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US11154516	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US11357741	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US11446258	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US11633369	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US9949937	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US9956186	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US10092525	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US9956183	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US10111840	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US10137095	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US10603288	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US10709671	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US10709674	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US11400055	GW RES LTD	Use of cannabidiol in the treatment of epilepsy	Oct, 2035 (12 years from now)
US11065209	GW RES LTD	Use of cannabidiol in the treatment of epilepsy	Oct, 2035 (12 years from now)
US10918608	GW RES LTD	Use of cannabidiol in the treatment of epilepsy	Oct, 2035 (12 years from now)
US11406623	GW RES LTD	Methods of treating tuberous sclerosis complex with cannabidiol and everolimus	Mar, 2041 (17 years from now)
US11160795	GW RES LTD	Methods of treating tuberous sclerosis complex with cannabidiol and everolimus	Mar, 2041 (17 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 28, 2023
Orphan Drug Exclusivity (ODE)	Jul 31, 2027
New Patient Population (NPP)	Jul 31, 2023

Drugs and Companies using CANNABIDIOL ingredient

NCE-1 date: 2022-09-28

Market Authorisation Date: 28 September, 2018

Treatment: Use for the treatment of absence seizures in patients with dravet syndrome; Use for the treatment of absence seizures in patients with lennox-gastaut syndrome; Use for the treatment of seizures in pat...

Dosage: SOLUTION;ORAL